Vaccines targeting the neovasculature of tumors

Vascular Cell

Volumn 3, Issue , 2011, Pages

  Matejuk, Agata ^a,b   Leng, Qixin ^a   Chou, Szu Ting ^a   Mixson, Archibald J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR PEPTIDE; BEVACIZUMAB; DENDRITIC CELL VACCINE; DNA VACCINE; ENDOGLIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GASTRIN RELEASING PEPTIDE; GELATINASE A; GEMCITABINE; LEGUMAIN; NAKED DNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RNA VACCINE; TUMOR CELL VACCINE; TUMOR ENDOTHELIAL VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 PEPTIDE 169; VEGFR2 VACCINE;

ANGIOGENESIS; ANTIANGIOGENIC GENE THERAPY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOID SYNDROME; CLINICAL TRIAL; COLON CARCINOMA; CYTOLYSIS; DENDRITIC CELL; DNA IMMUNIZATION; DNA VECTOR; DRUG CROSS REACTIVITY; DRUG TARGETING; ENDOTHELIUM CELL; FERTILITY; FIBROSARCOMA; GENE TARGETING; HUMAN; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PERICYTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; REVIEW; SIDE EFFECT; THROMBOSIS; TUMOR GROWTH; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR TUMOR; WOUND HEALING; WOUND HEALING IMPAIRMENT;

EID: 79955641941     PISSN: 2045824X     EISSN: None     Source Type: Journal    
DOI: 10.1186/2045-824X-3-7     Document Type: Review

References (143)

1. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Rosen LS, Cancer Control 2002 9 36 44 11965229 (Pubitemid 34457339)
2. Hypoxia-inducible factors: central regulators of the tumor phenotype. Gordan JD Simon MC, Curr Opin Genet Dev 2007 17 71 77 10.1016/j.gde.2006.12.006 17208433 (Pubitemid 46109295)
3. Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Gruber M Simon MC, Curr Opin Hematol 2006 13 169 174 10.1097/01.moh.0000219663.88409.35 16567961
4. Search for Clinical Trials-National Cancer Institute. http://www.cancer.gov/clinicaltrials/search
5. Tumor vasculature as target for therapeutic intervention. Fens MH Storm G Schiffelers RM, Expert Opin Investig Drugs 2010 19 1321 1338 10.1517/13543784.2010.524204 20946091
6. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Tammela T Zarkada G, Wallgard E Murtomaki A, Suchting S Wirzenius M, Waltari M Hellstrom M, Schomber T Peltonen R, et al. Nature 2008 454 656 660 10.1038/nature07083 18594512
7. Angiopoietin-2: development of inhibitors for cancer therapy. Hu B Cheng SY, Curr Oncol Rep 2009 11 111 116 10.1007/s11912-009-0017-3 19216842
8. Targeting tumor angiogenesis with gene therapy. Chen QR Zhang L, Gasper W Mixson AJ, Mol Genet Metab 2001 74 120 127 10.1006/mgme.2001.3223 11592809 (Pubitemid 32955153)
9. Off-tumor target - beneficial site for antiangiogenic cancer therapy? Cao Y, Nat Rev Clin Oncol 2010 7 604 608 10.1038/nrclinonc.2010.118 20683436
10. Angiogenesis: What can it offer for future medicine? Cao Y, Exp Cell Res 2010 316 1304 1308 10.1016/j.yexcr.2010.02.031 20206162
11. Optimizing the delivery of cancer drugs that block angiogenesis. Cao Y Langer R, Sci Transl Med 2010 2 15ps13
12. Genes expressed in human tumor endothelium. St Croix B Rago C Velculescu V Traverso G, Romans KE Montgomery E, Lal A Riggins GJ, Lengauer C Vogelstein B, Kinzler KW, Science 2000 289 1197 1202 10.1126/science.289.5482.1197 10947988 (Pubitemid 30650733)
13. Genes that distinguish physiological and pathological angiogenesis. Seaman S Stevens J, Yang MY Logsdon D, Graff-Cherry C St Croix B, Cancer Cell 2007 11 539 554 10.1016/j.ccr.2007.04.017 17560335 (Pubitemid 46856908)
14. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Boehm T Folkman J, Browder T O'Reilly MS, Nature 1997 390 404 407 10.1038/37126 9389480 (Pubitemid 28027321)
15. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Huang J Soffer SZ, Kim ES McCrudden KW, New T Manley CA, Middlesworth W O'Toole K, Yamashiro DJ Kandel JJ, Mol Cancer Res 2004 2 36 42 14757844 (Pubitemid 38167106)
16. Tumor-associated endothelial cells with cytogenetic abnormalities. Hida K Hida Y Amin DN Flint AF, Panigrahy D Morton CC, Klagsbrun M, Cancer Res 2004 64 8249 8255 10.1158/0008-5472.CAN-04-1567 15548691 (Pubitemid 39491762)
17. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Hida K Klagsbrun M, Cancer Res 2005 65 2507 2510 10.1158/0008-5472.CAN-05-0002 15805239 (Pubitemid 40490041)
18. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Ricci-Vitiani L Pallini R Biffoni M Todaro M, Invernici G Cenci T, Maira G Parati EA, Stassi G Larocca LM, De Maria R, Nature 2010 468 824 828 10.1038/nature09557 21102434
19. Glioblastoma stem-like cells give rise to tumour endothelium. Wang R Chadalavada K, Wilshire J Kowalik U, Hovinga KE Geber A, Fligelman B Leversha M, Brennan C Tabar V, Nature 2010 468 829 833 10.1038/nature09624 21102433
20. Fighting cancer by attacking its blood supply. Folkman J, Sci Am 1996 275 150 154 10.1038/scientificamerican0996-150 8701285
21. Antiangiogenic Therapy. Folkman J, Principles and Practice of Oncology Philadelphia: Lippincott-Raven, DeVita VT, Hellman S, Rosenberg SA, 1997 3075 3085
22. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Hurwitz H, Clin Colorectal Cancer 2004 4 Suppl 2 62 68 10.3816/CCC.2004.s.010 15479481
23. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eskens FA Sleijfer S, Eur J Cancer 2008 44 2350 2356 10.1016/j.ejca.2008.07.042 18789679
24. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Grothey A Ellis LM, Cancer J 2008 14 170 177 10.1097/PPO.0b013e318178d9de 18536556
25. Targeting the immune system in cancer. Chaudhuri D Suriano R, Mittelman A Tiwari RK, Curr Pharm Biotechnol 2009 10 166 184 10.2174/138920109787315114 19199949
26. Vaccines against human carcinomas: strategies to improve antitumor immune responses. Palena C Schlom J, J Biomed Biotechnol 2010 2010 380697 20300434
27. DNA vaccines: developing new strategies against cancer. Fioretti D Iurescia S, Fazio VM Rinaldi M, J Biomed Biotechnol 2010 2010 174378 20368780
28. Whole tumor antigen vaccines. Chiang CL Benencia F Coukos G, Semin Immunol 2010 22 132 143 10.1016/j.smim.2010.02.004 20356763
29. DNA vaccination strategies for anti-tumour effective gene therapy protocols. Signori E Iurescia S Massi E Fioretti D, Chiarella P De Robertis M, Rinaldi M Tonon G, Fazio VM, Cancer Immunol Immunother 2010 59 1583 1591 10.1007/s00262-010-0853-x 20390416
30. DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis. Reisfeld RA Niethammer AG, Luo Y Xiang R, Int Arch Allergy Immunol 2004 133 295 304 10.1159/000077009 14988601 (Pubitemid 38529223)
31. Harnessing Listeria monocytogenes to target tumors. Gravekamp C Paterson Y, Cancer Biol Ther 2010 9 257 265
32. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. Seavey MM Maciag PC Al-Rawi N Sewell D, Paterson Y, J Immunol 2009 182 5537 5546 10.4049/jimmunol.0803742 19380802
33. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Maciag PC Seavey MM Pan ZK Ferrone S, Paterson Y, Cancer Res 2008 68 8066 8075 10.1158/0008-5472.CAN-08- 0287 18829565
34. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Kaplan CD Kruger JA, Zhou H Luo Y, Xiang R Reisfeld RA, Vaccine 2006 24 6994 7002 10.1016/j.vaccine.2006.04.071 17050049 (Pubitemid 46107180)
35. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Xiang R Mizutani N Luo Y Chiodoni C, Zhou H Mizutani M, Ba Y Becker JC, Reisfeld RA, Cancer Res 2005 65 553 561 15695399
36. Use of attenuated bacteria as delivery vectors for DNA vaccines. Daudel D Weidinger G Spreng S, Expert Rev Vaccines 2007 6 97 110 10.1586/14760584.6.1.97 17280482 (Pubitemid 46232483)
37. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Lladser A Ljungberg K Tufvesson H Tazzari M, Roos AK Quest AF, Kiessling R, Cancer Immunol Immunother 2010 59 81 92 10.1007/s00262-009-0725-4 19526360
38. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Holmgren L Ambrosino E, Birot O Tullus C, Veitonmaki N Levchenko T, Carlson LM Musiani P, Iezzi M Curcio C, et al. Proc Natl Acad Sci USA 2006 103 9208 9213 10.1073/pnas.0603110103 16754857 (Pubitemid 43902557)
39. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. Lladser A Parraga M, Quevedo L Carmen Molina M, Silva S Ferreira A, Billetta R AF GQ, Immunobiology 2006 211 11 27 10.1016/j.imbio.2005.08.002 16446167 (Pubitemid 43150105)
40. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Zhu K Qin H Cha SC Neelapu SS, Overwijk W Lizee GA, Abbruzzese JL Hwu P, Radvanyi L Kwak LW, Chang DZ, Vaccine 2007 25 7955 7961 10.1016/j.vaccine.2006.10.026 17933439 (Pubitemid 47632978)
41. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. Nanni P Nicoletti G, De Giovanni C Landuzzi L, Di Carlo E Cavallo F, Pupa SM Rossi I, Colombo MP Ricci C, et al. J Exp Med 2001 194 1195 1205 10.1084/jem.194.9.1195 11696586 (Pubitemid 33055039)
42. Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor. Hu B Wei Y, Tian L Zhao X, Lu Y Wu Y, Yao B Liu J, Niu T Wen Y, et al. J Immunother 2005 28 236 244 10.1097/01.cji. 0000161394.11831.3f 15838380 (Pubitemid 40593989)
43. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Wada S Tsunoda T Baba T Primus FJ, Kuwano H Shibuya M, Tahara H, Cancer Res 2005 65 4939 4946 10.1158/0008-5472.CAN-04-3759 15930316 (Pubitemid 40740834)
44. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Tacken PJ de Vries IJM, Torensma R Figdor CG, Nature Reviews Immunology 2007 7 790 802 10.1038/nri2173 17853902 (Pubitemid 47480309)
45. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. Li Y Wang MN, Li H King KD, Bassi R Sun H, Santiago A Hooper AT, Bohlen P Hicklin DJ, J Exp Med 2002 195 1575 1584 10.1084/jem.20020072 12070285 (Pubitemid 34666071)
46. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-Transfected dendritic cells. Nair SK Morse M Boczkowski D Cumming RI, Vasovic L Gilboa E, Lyerly HK, Annals of Surgery 2002 235 540 549 10.1097/00000658-200204000-00013 11923611 (Pubitemid 34258354)
47. Synergy between tumor immunotherapy and antiangiogenic therapy. Nair S Boczkowski D, Moeller B Dewhirst M, Vieweg J Gilboa E, Blood 2003 102 964 971 10.1182/blood-2002-12-3738 12689940 (Pubitemid 36917791)
48. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Pellegatta S Poliani PL, Stucchi E Corno D, Colombo CA Orzan F, Ravanini M Finocchiaro G, Neuro Oncol 2010 12 377 388 20308315
49. The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model. Lai MD Yen MC, Lin CM Tu CF, Wang CC Lin PS, Yang HJ Lin CC, Genet Vaccines Ther 2009 7 2 10.1186/1479-0556-7-2 19178753
50. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Wei YQ Wang QR, Zhao X Yang L, Tian L Lu Y, Kang B Lu CJ, Huang MJ Lou YY, et al. Nat Med 2000 6 1160 1166 10.1038/80506 11017149
51. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Okaji Y Tsuno NH, Kitayama J Saito S, Takahashi T Kawai K, Yazawa K Asakage M, Hori N Watanabe T, et al. Cancer Science 2004 95 85 90 10.1111/j.1349-7006.2004.tb03175.x 14720332 (Pubitemid 38208412)
52. Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine. Scappaticci FA Nolan GP, Anticancer Res 2003 23 1165 1172 12820367 (Pubitemid 36754074)
53. Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line. Yoshiura K Nishishita T Nakaoka T Yamashita N, Yamashita N, Journal of Experimental & Clinical Cancer Research 2009 28 13
54. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Okaji Y Tsuno NH, Tanaka M Yoneyama S, Matsuhashi M Kitayama J, Saito S Nagura Y, Tsuchiya T Yamada J, et al. European Journal of Cancer 2008 44 383 390 10.1016/j.ejca.2007.10.018 18060766 (Pubitemid 351179625)
55. Vaccination with xenogeneic tumor endothelial proteins isolated in situ inhibits tumor angiogenesis and spontaneous metastasis. Zhang W Liu JN Tan XY, Int J Cancer 2009 125 124 132 10.1002/ijc.24362 19350628
56. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Shalaby F Rossant J Yamaguchi TP Gertsenstein M, Wu XF Breitman ML, Schuh AC, Nature 1995 376 62 66 10.1038/376062a0 7596435
57. Antiangiogenic and antivascular therapy for cancer. Taraboletti G Margosio B, Curr Opin Pharmacol 2001 1 378 384 10.1016/S1471-4892(01)00065-0 11710736 (Pubitemid 33585987)
58. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Wei YQ Huang MJ, Yang L Zhao X, Tian L Lu Y, Shu JM Lu CJ, Niu T Kang B, et al. Proc Natl Acad Sci USA 2001 98 11545 11550 10.1073/pnas.191112198 11553767 (Pubitemid 32928765)
59. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Niethammer AG Xiang R, Becker JC Wodrich H, Pertl U Karsten G, Eliceiri BP Reisfeld RA, Nat Med 2002 8 1369 1375 10.1038/nm794 12415261 (Pubitemid 36019421)
60. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Hou JM Liu JY, Yang L Zhao X, Tian L Ding ZY, Wen YJ Niu T, Xiao F Lou YY, et al. Oncology 2005 69 81 87 10.1159/000087303 16088235 (Pubitemid 41207061)
61. T cell-mediated suppression of angiogenesis results in tumor protective immunity. Zhou H Luo Y, Mizutani M Mizutani N, Reisfeld RA Xiang R, Blood 2005 106 2026 2032 10.1182/blood-2005-03-0969 15920006 (Pubitemid 41291716)
62. Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. Dong Y Qian J Ibrahim R Berzofsky JA, Khleif SN, J Immunother 2006 29 32 40 10.1097/01.cji.0000175494. 13476.56 16365598
63. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice. Luo Y Markowitz D Xiang R Zhou H, Reisfeld RA, Vaccine 2007 25 1409 1415 10.1016/j.vaccine.2006.10.043 17113202 (Pubitemid 46091820)
64. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1. Wang YS Wang GQ, Wen YJ Wang L, Chen XC Chen P, Kan B Li J, Huang C Lu Y, et al. Clin Cancer Res 2007 13 6779 6787 10.1158/1078-0432.CCR-07-1587 18006780 (Pubitemid 350206816)
65. Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models. Xie K Bai RZ, Wu Y Liu Q, Liu K Wei YQ, Genet Vaccines Ther 2009 7 10 10.1186/1479-0556-7-10 19545394
66. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Miyazawa M Ohsawa R, Tsunoda T Hirono S, Kawai M Tani M, Nakamura Y Yamaue H, Cancer Sci 2010 101 433 439 10.1111/j.1349-7006.2009.01416.x 19930156
67. Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. Zuo SG Chen Y, Wu ZP Liu X, Liu C Zhou YC, Wu CL Jin CG, Gu YL Li J, et al. Biol Pharm Bull 2010 33 174 182 10.1248/bpb.33.174 20118536
68. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Yang D Chertov O Bykovskaia SN Chen Q, Buffo MJ Shogan J, Anderson M Schroder JM, Wang JM Howard OM, Oppenheim JJ, Science 1999 286 525 528 10.1126/science.286.5439.525 10521347
69. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Biragyn A Ruffini PA Leifer CA Klyushnenkova E, Shakhov A Chertov O, Shirakawa AK Farber JM, Segal DM Oppenheim JJ, Kwak LW, Science 2002 298 1025 1029 10.1126/science.1075565 12411706 (Pubitemid 35247310)
70. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Lee YH Tokunaga T, Oshika Y Suto R, Yanagisawa K Tomisawa M, Fukuda H Nakano H, Abe S Tateishi A, et al. Eur J Cancer 1999 35 1089 1093 10.1016/S0959-8049(99)00073-8 10533453 (Pubitemid 29339192)
71. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Oshika Y Nakamura M Tokunaga T Ozeki Y, Fukushima Y Hatanaka H, Abe Y Yamazaki H, Kijima H Tamaoki N, Ueyama Y, Int J Oncol 1998 12 541 544 9472090 (Pubitemid 28097280)
72. [Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice]. Li XH Tang L Liu D Sun HM, Zhou CC Tan LS, Wang LP Zhang PD, Zhang SQ, Ai Zheng 2006 25 1221 1226 17059764
73. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Rad FH Le Buanec H Paturance S Larcier P, Genne P Ryffel B, Bensussan A Bizzini B, Gallo RC Zagury D, Uzan G, Proc Natl Acad Sci USA 2007 104 2837 2842 10.1073/pnas.0611022104 17301234 (Pubitemid 46327966)
74. VEGF-A splicing: the key to anti-angiogenic therapeutics? Harper SJ Bates DO, Nat Rev Cancer 2008 8 880 887 10.1038/nrc2505 18923433
75. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Varey AH Rennel ES, Qiu Y Bevan HS, Perrin RM Raffy S, Dixon AR Paraskeva C, Zaccheo O Hassan AB, et al. Br J Cancer 2008 98 1366 1379 10.1038/sj.bjc.6604308 18349829 (Pubitemid 351543576)
76. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Plum SM Holaday JW, Ruiz A Madsen JW, Fogler WE Fortier AH, Vaccine 2000 19 1294 1303 10.1016/S0264- 410X(00)00210-3 11137269 (Pubitemid 32008298)
77. Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction. Plum SM Vu HA Mercer B Fogler WE, Fortier AH, Immunopharmacol Immunotoxicol 2004 26 29 41 10.1081/IPH-120029942 15106730 (Pubitemid 38495960)
78. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. He QM Wei YQ, Tian L Zhao X, Su JM Yang L, Lu Y Kan B, Lou YY Huang MJ, et al. J Biol Chem 2003 278 21831 21836 10.1074/jbc.M300880200 12651849 (Pubitemid 36792588)
79. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Nanda A Carson-Walter EB Seaman S Barber TD, Stampfl J Singh S, Vogelstein B Kinzler KW, St Croix B, Cancer Res 2004 64 817 820 10.1158/0008-5472.CAN-03-2408 14871805 (Pubitemid 38176877)
80. Cell surface tumor endothelial markers are conserved in mice and humans. Carson-Walter EB Watkins DN, Nanda A Vogelstein B, Kinzler KW St Croix B, Cancer Res 2001 61 6649 6655 11559528 (Pubitemid 32896479)
81. Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome. Venanzi FM Petrini M Fiammenghi L Bolli E, Granato AM Ridolfi L, Gabrielli F Barucca A, Concetti A Ridolfi R, Riccobon A, Cancer Immunol Immunother 2010 59 27 34 10.1007/s00262-009-0717-4 19440709
82. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag. Felicetti P Mennecozzi M, Barucca A Montgomery S, Orlandi F Manova K, Houghton AN Gregor PD, Concetti A Venanzi FM, Cytotherapy 2007 9 23 34 10.1080/14653240601048369
83. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. Ruan Z Yang Z Wang Y Wang H, Chen Y Shang X, Yang C Guo S, Han J Liang H, Wu Y, J Immunother 2009 32 486 491 10.1097/CJI. 0b013e3181a1d134 19609240
84. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Dales JP Garcia S Andrac L Carpentier S, Ramuz O Lavaut MN, Allasia C Bonnier P, Charpin C, Int J Oncol 2004 24 1197 1204 15067342
85. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Takahashi N Kawanishi-Tabata R Haba A Tabata M, Haruta Y Tsai H, Seon BK, Clin Cancer Res 2001 7 524 532 11297243 (Pubitemid 32707974)
86. Anti-cancer therapies targeting the tumor stroma. Hofmeister V Schrama D Becker JC, Cancer Immunol Immunother 2008 57 1 17 10.1007/s00262-007-0365-5 17661033 (Pubitemid 350043655)
87. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Tan GH Wei YQ, Tian L Zhao X, Yang L Li J, He QM Wu Y, Wen YJ Yi T, et al. Eur J Immunol 2004 34 2012 2021 10.1002/eji.200424933 15214049 (Pubitemid 39256082)
88. Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. Tan GH Tian L, Wei YQ Zhao X, Li J Wu Y, Wen YJ Yi T, Ding ZY Kan B, et al. Int J Cancer 2004 112 701 706 10.1002/ijc.20449 15382054 (Pubitemid 39425953)
89. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. Troyanovsky B Levchenko T Mansson G Matvijenko O, Holmgren L, J Cell Biol 2001 152 1247 1254 10.1083/jcb.152.6.1247 11257124 (Pubitemid 34280181)
90. Angiomotin regulates endothelial cell-cell junctions and cell motility. Bratt A Birot O Sinha I Veitonmaki N, Aase K Ernkvist M, Holmgren L, J Biol Chem 2005 280 34859 34869 10.1074/jbc.M503915200 16043488 (Pubitemid 41504620)
91. Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. Jiang WG Watkins G Douglas-Jones A Holmgren L, Mansel RE, BMC Cancer 2006 6 16 10.1186/1471-2407-6-16 16430777
92. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Peters KG Coogan A Berry D Marks J, Iglehart JD Kontos CD, Rao P Sankar S, Trogan E, Br J Cancer 1998 77 51 56 10.1038/bjc.1998.8 9459145 (Pubitemid 28029772)
93. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Lin P Buxton JA Acheson A Radziejewski C, Maisonpierre PC Yancopoulos GD, Channon KM Hale LP, Dewhirst MW George SE, Peters KG, Proc Natl Acad Sci USA 1998 95 8829 8834 10.1073/pnas.95.15.8829 9671764 (Pubitemid 28350574)
94. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Luo Y Wen YJ, Ding ZY Fu CH, Wu Y Liu JY, Li Q He QM, Zhao X Jiang Y, et al. Clin Cancer Res 2006 12 1813 1819 10.1158/1078-0432.CCR-05-1990 16551866
95. Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. Ramage JM Metheringham R Conn A Spendlove I, Moss RS Patton DT, Murray JC Rees RC, Durrant LG, Int J Cancer 2004 110 245 250 10.1002/ijc.20120 15069689 (Pubitemid 38580398)
96. Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. Fu C Bardhan S, Cetateanu ND Wamil BD, Wang Y Yan HP, Shi E Carter C, Venkov C Yakes FM, et al. Clin Cancer Res 2001 7 4182 4194 11751519 (Pubitemid 34044644)
97. Studies on group B beta-hemolytic Streptococcus. II. Effects on pulmonary hemodynamics and vascular permeability in unanesthetized sheep. Rojas J Green RS, Hellerqvist CG Olegard R, Brigham KL Stahlman MT, Pediatr Res 1981 15 899 904 7017566 (Pubitemid 11070244)
98. Isolation and identification of the group B streptococcal toxin CM101 from infants with sepsis. Sundell HW Yan H, Carter CE Wamil BD, Wu K Gaddipati R, Li D Hellerqvist CG, J Pediatr 2000 137 338 344 10.1067/mpd.2000.107839 10969257
99. Regulatory mechanisms for the expression and activity of platelet-derived growth factor receptor. Funa K Uramoto H, Acta Biochim Pol 2003 50 647 658 14515146 (Pubitemid 38623798)
100. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Ostman A, Cytokine Growth Factor Rev 2004 15 275 286 10.1016/j.cytogfr.2004.03.002 15207817 (Pubitemid 38781051)
101. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Song S Ewald AJ Stallcup W Werb Z, Bergers G, Nat Cell Biol 2005 7 870 879 10.1038/ncb1288 16113679 (Pubitemid 41486287)
102. Survivin minigene DNA vaccination is effective against neuroblastoma. Fest S Huebener N, Bleeke M Durmus T, Stermann A Woehler A, Baykan B Zenclussen AC, Michalsky E Jaeger IS, et al. Int J Cancer 2009 125 104 114 10.1002/ijc.24291 19291796
103. Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma. Hajri A Balboni G Koenig M Garaud JC, Damge C, Cancer Res 1992 52 3726 3732 1319829
104. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. Lango MN Dyer KF Lui VW Gooding WE, Gubish C Siegfried JM, Grandis JR, J Natl Cancer Inst 2002 94 375 383 11880476 (Pubitemid 34257481)
105. Gastrin-releasing peptide is a growth factor for human neuroblastomas. Kim S Hu W, Kelly DR Hellmich MR, Evers BM Chung DH, Ann Surg 2002 235 621 629 discussion 629-630 10.1097/00000658-200205000-00003 11981207
106. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Cuttitta F Carney DN Mulshine J Moody TW, Fedorko J Fischler A, Minna JD, Nature 1985 316 823 826 10.1038/316823a0 2993906 (Pubitemid 15003742)
107. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Carney DN Cuttitta F, Moody TW Minna JD, Cancer Res 1987 47 821 825 3026617 (Pubitemid 17027980)
108. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Yano T Pinski J, Groot K Schally AV, Cancer Res 1992 52 4545 4547 1643647
109. Gastrin releasing peptide GRP(14-27) in human breast cancer cells and in small cell lung cancer. Vangsted AJ Andersen EV, Nedergaard L Zeuthen J, Breast Cancer Res Treat 1991 19 119 128 10.1007/BF01980942 1661625
110. Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours. Scott N Millward E Cartwright EJ Preston SR, Coletta PL, J Clin Pathol 2004 57 189 192 10.1136/jcp.2003.10660 14747448 (Pubitemid 38177761)
111. Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Martinez A Zudaire E Julian M Moody TW, Cuttitta F, Oncogene 2005 24 4106 4113 15750618 (Pubitemid 40897056)
112. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Levine L Lucci JA Pazdrak B Cheng JZ, Guo YS Townsend CM Jr, Hellmich MR, Cancer Res 2003 63 3495 3502 12839933 (Pubitemid 36793027)
113. Bombesin induces angiogenesis and neuroblastoma growth. Kang J Ishola TA Baregamian N Mourot JM, Rychahou PG Evers BM, Chung DH, Cancer Lett 2007 253 273 281 10.1016/j.canlet.2007.02.007 17383815 (Pubitemid 47017542)
114. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Cornelio DB Roesler R Schwartsmann G, Ann Oncol 2007 18 1457 1466 10.1093/annonc/mdm058 17351255 (Pubitemid 47365477)
115. A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo. Guojun W Wei G, Kedong O Yi H, Yanfei X Qingmei C, Yankai Z Jie W, Hao F Taiming L, et al. Endocr Relat Cancer 2008 15 149 159 10.1677/ERC-07-0224 18310283 (Pubitemid 351449735)
116. Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo. Fang J Lu Y, Ouyang K Wu G, Zhang H Liu Y, Chen Y Lin M, Wang H Jin L, et al. Clin Vaccine Immunol 2009 16 1033 1039 10.1128/CVI.00046-09 19458203
117. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Liu C Sun C Huang H Janda K, Edgington T, Cancer Res 2003 63 2957 2964 12782603 (Pubitemid 36667169)
118. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Murthy RV Arbman G Gao J Roodman GD, Sun XF, Clin Cancer Res 2005 11 2293 2299 10.1158/1078-0432.CCR-04-1642 15788679 (Pubitemid 40490189)
119. Targeting tumor-associated macrophages as a novel strategy against breast cancer. Luo Y Zhou H Krueger J Kaplan C, Lee SH Dolman C, Markowitz D Wu W, Liu C Reisfeld RA, Xiang R, J Clin Invest 2006 116 2132 2141 10.1172/JCI27648 16862213 (Pubitemid 44162322)
120. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Lewen S Zhou H, Hu HD Cheng T, Markowitz D Reisfeld RA, Xiang R Luo Y, Cancer Immunol Immunother 2008 57 507 515 10.1007/s00262-007-0389-x 17786443 (Pubitemid 351170534)
121. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Rasmussen HS McCann PP, Pharmacol Ther 1997 75 69 75 10.1016/S0163-7258(97)00023-5 9364582 (Pubitemid 27444688)
122. Combination therapy including a gelatinase inhibitor and cytoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Anderson IC Shipp MA, Docherty AP Teicher BA, Cancer Research 1996 56 715 718 8631001 (Pubitemid 26060511)
123. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Su JM Wei YQ, Tian L Zhao X, Yang L He QM, Wang Y Lu Y, Wu Y Liu F, et al. Cancer Res 2003 63 600 607 12566302 (Pubitemid 36158137)
124. The Trouble with Inhibitors. Smyth E, Signalling scissors: new perspectives on proteases; Brescia, Italy Nature Publishing Group 2003
125. MMP inhibitors: glimmers of hope amidst clinical failures. Dove A, Nat Med 2002 8 95 10.1038/nm0202-95 11821877 (Pubitemid 34155108)
126. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Overall CM Kleifeld O, Br J Cancer 2006 94 941 946 10.1038/sj.bjc. 6603043 16538215
127. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Overall CM Kleifeld O, Nat Rev Cancer 2006 6 227 239 10.1038/nrc1821 16498445 (Pubitemid 43292566)
128. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eskens FA Dumez H, Hoekstra R Perschl A, Brindley C Bottcher S, Wynendaele W Drevs J, Verweij J van Oosterom AT, Eur J Cancer 2003 39 917 926 10.1016/S0959-8049(03) 00057-1 12706360 (Pubitemid 36428623)
129. Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3. Lou YY Wei YQ, Yang L Zhao X, Tian L Lu Y, Wen YJ Liu F, Huang MJ Kang B, et al. Immunol Invest 2002 31 51 69 10.1081/IMM-120003221 11990463 (Pubitemid 34311284)
130. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Liu JY Wei YQ, Yang L Zhao X, Tian L Hou JM, Niu T Liu F, Jiang Y Hu B, et al. Blood 2003 102 1815 1823 10.1182/blood-2002-12-3772 12750177 (Pubitemid 37022578)
131. Bevacizumab in the Treatment of Patients with Advanced Breast Cancer: Where have We Landed? Dirix LY Van Dam PA, Prove PA Vermeulen PB, Ther Adv Med Oncol 2010 2 331 342 10.1177/1758834010376301
132. Human NK cells lyse organ-specific endothelial cells: analysis of adhesion and cytotoxic mechanisms. Bielawska-Pohl A Crola C Caignard A Gaudin C, Dus D Kieda C, Chouaib S, J Immunol 2005 174 5573 5582 15843556 (Pubitemid 40593198)
133. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Tsuji K Hamada T, Uenaka A Wada H, Sato E Isobe M, Asagoe K Yamasaki O, Shiku H Ritter G, et al. Cancer Immunol Immunother 2008 57 1429 1437 10.1007/s00262-008-0478-5 18311489
134. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Ostrand-Rosenberg S, Cancer Immunol Immunother 2010 59 1593 1600 10.1007/s00262-010-0855-8 20414655
135. The anti-angiogenic activity of IL-12 is increased in iNOS-/- mice and involves NK cells. Bielawska-Pohl A Blesson S, Benlalam H Trenado A, Opolon P Bawa O, Rouffiac V Dus D, Kieda C Chouaib S, J Mol Med 2010 88 775 784 10.1007/s00109-010-0620-7 20383693
136. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Osada T Clay T Hobeika A Lyerly HK, Morse MA, Cancer Immunol Immunother 2006 55 1122 1131 10.1007/s00262-005-0089-3 16273350 (Pubitemid 43800727)
137. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Sidky YA Borden EC, Cancer Res 1987 47 5155 5161 2441862 (Pubitemid 17146488)
138. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor-cell lines. Majewski S Szmurlo A Marczak M Jablonska S, Bollag W, Int J Cancer 1994 57 81 85 10.1002/ijc.2910570115 7512078 (Pubitemid 24117104)
139. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Slaton JW Perrotte P Inoue K Dinney CP, Fidler IJ, Clin Cancer Res 1999 5 2726 2734 10537335 (Pubitemid 29493945)
140. Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL. Benlalam H Jalil A, Hasmim M Pang B, Tamouza R Mitterrand M, Godet Y Lamerant N, Robert C Avril MF, et al. J Immunol 2009 182 2654 2664 10.4049/jimmunol.0800815 19234159
141. Targeting the prostate for destruction through a vascular address. Arap W Haedicke W, Bernasconi M Kain R, Rajotte D Krajewski S, Ellerby HM Bredesen DE, Pasqualini R Ruoslahti E, Proc Natl Acad Sci USA 2002 99 1527 1531 10.1073/pnas.241655998 11830668 (Pubitemid 34136526)
142. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Trepel M Arap W Pasqualini R, Curr Opin Chem Biol 2002 6 399 404 10.1016/S1367-5931(02)00336-8 12023122 (Pubitemid 34522068)
143. Vascular homing peptides with cell-penetrating properties. Ruoslahti E Duza T, Zhang L, Curr Pharm Des 2005 11 3655 3660 10.2174/138161205774580787 16305501 (Pubitemid 41630991)